PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies
This study will evaluate the safety of PD-1 knockout EBV-CTL cells in treating EBV (Epstein-Barr virus) positive advanced stage malignancies. Blood samples will also be collected for research purposes.
Stage IV Gastric Carcinoma|Stage IV Nasopharyngeal Carcinoma|T-Cell Lymphoma Stage IV|Stage IV Adult Hodgkin Lymphoma|Stage IV Diffuse Large B-Cell Lymphoma
DRUG: Fludarabine|DRUG: Cyclophosphamide|DRUG: Interleukin-2
Number of participants with Adverse Events using Common Terminology Criteria for Adverse Events (CTCAE v4.0) in patients, 6 months
Response Rate, 90 days|Progression free survival (PFS), up to 1 year|Overall Survival (OS), up to 3 years|The duration of the normalization of tumor marker, up to 3 years|Interferon-Î³ change of T cells in the peripheral blood stimulated by tumor antigens, Baseline and 1 month, 3 months and 6 months|Th1/Th2 change in the peripheral blood, Baseline and 1 month, 3 months and 6 months
This is a study of CRISPR-Cas9 mediated PD-1 knockout-T cells from autologous origin. Patients are assigned to receive 4 circles of cell therapy. The safety and clinical response are evaluated. Biomarkers and immunological markers are also monitored.